Clinical trial
Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney…
NCT00035308 · La Jolla Pharmaceutical Company, Industry · Completed
Key facts
| NCT number | NCT00035308 |
|---|---|
| Title | Safety and Efficacy Study of LJP 394 (Abetimus Sodium) to Treat Lupus Kidney Disease |
| Official title | A Randomized, Double-Blind, Placebo-Controlled, Multicenter Safety and Efficacy Trial of LJP 394 in Systemic Lupus Erythematosus (SLE) Patients With a History of Renal Disease |
| Lead sponsor | La Jolla Pharmaceutical Company, Industry |
| Status | Completed |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Immunologic Diseases, Autoimmune Diseases, Systemic Lupus Erythematosus, Lupus Nephritis, Lupus Glomerulonephritis |
| Intervention type | Drug |
| Interventions | Abetimus sodium (LJP 394) |
| Enrollment | 330 |
| Completion | Dec 1, 2002 |
| First posted | May 3, 2002 |
| Last update posted | Sep 25, 2006 |
| Countries | Austria, Canada, France, Germany, Italy, Mexico, Spain, Sweden, United Kingdom, United States |
At a glance
- 10–99 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: